Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines

Vaccine

Volumn 21, Issue 13-14, 2003, Pages 1336-1347

  Cox, S J ^a   Aggarwal, N ^a   Statham, R J ^a   Barnett, P V ^a  

^a INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

Antibody; Cytokine; Foot and mouth disease vaccine; Immune responses

Indexed keywords

ANTIBODY; CYTOKINE; FOOT AND MOUTH DISEASE VACCINE; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DRUG FORMULATION; DRUG POTENCY; EMERGENCY TREATMENT; EPIDEMIC; FOOT AND MOUTH DISEASE; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION PREVENTION; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROVOCATION TEST; REVACCINATION; SEROCONVERSION; SHEEP; SPECIES COMPARISON; SWINE; VACCINATION;

ANIMALS; ANTIBODIES, VIRAL; CYTOKINES; FOOT-AND-MOUTH DISEASE VIRUS; IMMUNOGLOBULIN ISOTYPES; NEUTRALIZATION TESTS; SHEEP; SWINE; VACCINATION; VIRAL VACCINES;

EID: 0037471411     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00691-6     Document Type: Article

References (32)

1. Barteling S.J., Vreeswijk J. Developments in foot-and-mouth vaccines. Vaccine. 9:1991;75-88.
2. Doel T.R. Natural and vaccine-induced immunity to foot-and-mouth disease: the prospects for improved vaccines. Rev. Sci. Tech. Off. Int. Epiz. 15(3):1996;883-911.
3. Doel T.R. Optimisation of the immune response to foot-and-mouth disease vaccines. Vaccine. 17:1999;1767-1771.
4. Anderson E.C., Masters R.C., Mowat G.N. Immune response of pigs to inactivated foot-and-mouth disease vaccines. Response to emulsion vaccines. Res. Vet. Sci. 12:1971;342-350.
5. Doel T.R., Williams L., Barnett P.V. Emergency vaccination against foot-and-mouth disease: rate of development of immunity and its implications for the carrier state. Vaccine. 12:1994;592-600.
6. Salt JS, Williams L, Statham R, Barnett PV. Further studies on the rate of development of protection in cattle given emergency vaccination against FMD. Report of the session of the Standing Technical Committee of the European Commission for the Control of Foot-and-Mouth Disease. Appendix 17. Moedling, Vienna, Austria, 1995. p. 90-7.
7. Salt J.S., Barnett P.V., Dani P., Williams L. Emergency vaccination of pigs against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine. 16(7):1998;746-754.
8. Cox S.J., Barnett P.V., Dani P., Salt J.S. Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine. 17:1999;1858-1868.
9. Barnett P.V., Cox S.J., Aggarwal N., Gerber H., McCullough K.C. Further studies on the early protective responses in pigs following immunisation with high potency foot-and-mouth disease vaccine. Vaccine. 20:2002;3197-3208.
10. Medzhitov R., Janeway C.A. Innate immunity: the virtues of a non-clonal system of recognition. Cell. 91:1997;295-298.
11. Golding S.M., Hedger R.S., Talbot P. Radial immuno-diffusion and serum neutralisation techniques for the assay of antibodies to swine vesicular disease. Res. Vet. Sci. 20:1976;142-147.
12. Salt J.S., Mulcahy G., Kitching R.P. Isotype-specific antibody responses to foot-and-mouth disease virus in sera and secretions of carrier and non-carrier cattle. Epidemiol. Infect. 117:1996;349-360.
13. Snowdon W.A. Growth of foot-and-mouth disease virus in monolayer cultures of calf thyroid cells. Nature. 210:1966;1079-1080.
14. Gomes I. Foot-and-mouth disease: reaction of convalescent pigs to homologous virus exposure. Bol. Centr. Panam Fiebre Aftosa. 26:1977;18-22.
15. McKercher P.D., Giordano A.R. Foot-and-mouth disease in swine. I. The immune response of swine to chemically treated and non-treated foot-and-mouth disease virus. Arch. Ges. Virusforsc. 20(1):1967;39-53.
16. Barnett P.V., Pullen L., Williams L., Doel T.R. International Bank for foot-and-mouth disease vaccine assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants. Vaccine. 14(13):1996;1187-1198.
17. Barnett P.V., Carabib H. A review of emergency foot-and-mouth disease (FMD) vaccines. Vaccine. 20:2002;1505-1514.
18. Ouldridge E.J., Francis M.J., Black L. Antibody responses of pigs to foot-and-mouth disease oil emulsion vaccine: the antibody classes involved. Res. Vet. Sci. 32:1982;327-331.
19. Cowan K.M. Antibody responses to viral antigens. Adv. Immunol. 17:1973;195-255.
20. Mulcahy G., Gale C., Roberson P., Iyisan S., DiMarchi R.D., Doel T.R. Isotype responses of infected virus-vaccinated and peptide vaccinated cattle to foot-and-mouth disease virus. Vaccine. 8:1990;249-256.
21. Donaldson A.I., Alexandersen S. Relative resistance to infection by natural aerosols of FMD virus. Vet. Rec. 148:2001;600-602.
22. Alexandersen S, Donaldson AI. Further studies to quantify the dose of natural aerosols of foot-and-mouth disease virus for pigs. Report of the session of the Standing Technical Committee of the European Commission for the Control of Foot-and-Mouth Disease. Appendix 30. Island of Moen, Denmark, 2001. p. 142-52.
23. 1 Lausanne. Epidemiol. Infect. 128:2002;301-312.
24. Alexandersen S., Donaldson A.I. Further studies to quantify the dose of natural aerosols of foot-and-mouth disease virus for pigs. Epidemiol. Infect. 128:2002;313-323.
25. Donaldson A.I., Ferris N.P., Gloster J. Air sampling of pigs infected with foot-and-mouth disease virus: comparison of Litton and cyclone samplers. Res. Vet. Sci. 33:1982;384-385.
26. Cox JC, Coulter AR. Advances in adjuvant technology amd application. In: Yong WK, editor. Animal parasite control utilizing biotechnology. Boca Raton: CRC Press; 1992. p. 49-112.
27. Cox J.C., Coulter A.R. Adjuvants - a classification and review of their modes of action. Vaccine. 15(3):1997;248-256.
28. Van Snick J. Interleukin-6 - an overview. Annu. Rev. Immunol. 8:1990;253-278.
29. Arnold R., König B., Galatti H., Werchau H., König W. Cytokines (IL-8, IL-6, TNF-α) and soluble TNF receptor-I release from human peripheral blood mononuclear cells after respiratory syncytial virus infection. Immunology. 85:1995;364-372.
30. Van Damme J., Decock B., Conings R., Lenaerts J.P., Opdenakker G., Billiau A. The chemotactic activity for granulocytes produced by virally infected fibroblasts is identical to monocyte-derived interleukin-8. Eur. J. Immunol. 19:1989;1189-1194.
31. Choi A.M., Jacoby D.B. Influenza virus A infection induces IL-8 gene expression in human airway epithelial cells. FEBS Lett. 309:1992;327-329.
32. Baggiolini M., Loetscher P., Moser B. Interleukin-8 and the chemokine family. Int. J. Immunopharmacol. 17:1995;103-108.